127 related articles for article (PubMed ID: 8271778)
21. Heroin use among female adolescents: the role of partner influence in path of initiation and route of administration.
Eaves CS
Am J Drug Alcohol Abuse; 2004; 30(1):21-38. PubMed ID: 15083552
[TBL] [Abstract][Full Text] [Related]
22. [Heroin addiction].
Hosztafi S
Acta Pharm Hung; 2011; 81(4):173-83. PubMed ID: 22329304
[TBL] [Abstract][Full Text] [Related]
23. [Sex cases of sudden death after snorting heroin analyzed. Reduced tolerance in periodic abuse a danger both in snorting and injecting].
Rajs J; Fugelstad A
Lakartidningen; 2000 Apr; 97(15):1834-5. PubMed ID: 10815412
[TBL] [Abstract][Full Text] [Related]
24. Choice between money and intranasal heroin in morphine-maintained humans.
Comer SD; Collins ED; Fischman MW
Behav Pharmacol; 1997 Dec; 8(8):677-90. PubMed ID: 9832953
[TBL] [Abstract][Full Text] [Related]
25. Inhalation exposure to volatilized opioids produces antinociception in mice.
Lichtman AH; Meng Y; Martin BR
J Pharmacol Exp Ther; 1996 Oct; 279(1):69-76. PubMed ID: 8858977
[TBL] [Abstract][Full Text] [Related]
26. Changes in route of drug administration among continuing heroin users: outcomes 1 year after intake to treatment.
Gossop M; Stewart D; Marsden J; Kidd T; Strang J
Addict Behav; 2004 Aug; 29(6):1085-94. PubMed ID: 15236809
[TBL] [Abstract][Full Text] [Related]
27. The pharmacokinetics of heroin in patients with chronic pain.
Inturrisi CE; Max MB; Foley KM; Schultz M; Shin SU; Houde RW
N Engl J Med; 1984 May; 310(19):1213-7. PubMed ID: 6709027
[TBL] [Abstract][Full Text] [Related]
28. Dose-concentration relationships in hair from subjects in a controlled heroin-maintenance program.
Kintz P; Bundeli P; Brenneisen R; Ludes B
J Anal Toxicol; 1998; 22(3):231-6. PubMed ID: 9602941
[TBL] [Abstract][Full Text] [Related]
29. The duration time of urine morphine detection in heroin addicts by radioimmunoassay.
Narongchai P; Sribanditmonkol P; Thampithug S; Narongchai S; Chitivuthikarn C
J Med Assoc Thai; 2002 Jan; 85(1):82-6. PubMed ID: 12075726
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine.
Zandvliet AS; Huitema AD; de Jonge ME; den Hoed R; Sparidans RW; Hendriks VM; van den Brink W; van Ree JM; Beijnen JH
Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):71-9. PubMed ID: 15667599
[TBL] [Abstract][Full Text] [Related]
31. Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children.
Kidd S; Brennan S; Stephen R; Minns R; Beattie T
Arch Dis Child; 2009 Dec; 94(12):974-8. PubMed ID: 19793724
[TBL] [Abstract][Full Text] [Related]
32. Feasibility and acceptability of an intranasal diamorphine spray as an alternative to injectable diamorphine for maintenance treatment.
Mitchell TB; Lintzeris N; Bond A; Strang J
Eur Addict Res; 2006; 12(2):91-5. PubMed ID: 16543744
[TBL] [Abstract][Full Text] [Related]
33. Acute physiological and behavioral effects of intranasal methamphetamine in humans.
Hart CL; Gunderson EW; Perez A; Kirkpatrick MG; Thurmond A; Comer SD; Foltin RW
Neuropsychopharmacology; 2008 Jul; 33(8):1847-55. PubMed ID: 17851535
[TBL] [Abstract][Full Text] [Related]
34. Acute effects of intravenous heroin on the hypothalamic-pituitary-adrenal axis response: a controlled trial.
Walter M; Gerber H; Kuhl HC; Schmid O; Joechle W; Lanz C; Brenneisen R; Schächinger H; Riecher-Rössler A; Wiesbeck GA; Borgwardt SJ
J Clin Psychopharmacol; 2013 Apr; 33(2):193-8. PubMed ID: 23422375
[TBL] [Abstract][Full Text] [Related]
35. Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study.
Dunn KE; Brands B; Marsh DC; Bigelow GE
Psychopharmacology (Berl); 2018 Apr; 235(4):971-981. PubMed ID: 29270641
[TBL] [Abstract][Full Text] [Related]
36. Different routes of heroin intake cause various heroin-induced leukoencephalopathies.
Cheng MY; Chin SC; Chang YC; Wu T; Lim SN; Hsieh HY; Hsu JL; Chang CW; Tseng WJ; Li HT; Chiang HI; Chang BL; Tsai MH; Ro LS
J Neurol; 2019 Feb; 266(2):316-329. PubMed ID: 30478618
[TBL] [Abstract][Full Text] [Related]
37. Team research methods for studying intranasal heroin use and its HIV risks.
Ouellet LJ; Wiebel WW; Jimenez AD
NIDA Res Monogr; 1995; 157():182-211. PubMed ID: 8684437
[TBL] [Abstract][Full Text] [Related]
38. First use of heroin: changes in route of administration over time.
Strang J; Griffiths P; Powis B; Gossop M
BMJ; 1992 May; 304(6836):1222-3. PubMed ID: 1515792
[No Abstract] [Full Text] [Related]
39. Mast cell mediator tryptase levels after inhalation or intravenous administration of high doses pharmaceutically prepared heroin.
Rook EJ; van Zanten AP; Van den Brink W; van Ree JM; Beijnen JH
Drug Alcohol Depend; 2006 Dec; 85(3):185-90. PubMed ID: 16765536
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature.
Rook EJ; Huitema AD; van den Brink W; van Ree JM; Beijnen JH
Curr Clin Pharmacol; 2006 Jan; 1(1):109-18. PubMed ID: 18666382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
